Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 119 of the 121 references it cites were found in a registry or an index; 62 of the 229 sources its claims cite were checked for support.

Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review

Open access
Tasabehji, Dana, Saleh, Sanaz, Mokadem, Mohamad · 2025 · Journal of Clinical Medicine

Abstract

This review examines the effectiveness of various surgical and endoscopic bariatric interventions in improving several components of metabolic dysfunction-associated steatotic liver disease (MASLD). Roux-en-Y gastric bypass (RYGB) consistently showed substantial long-term reductions in liver fat, inflammation, and fibrosis, achieving resolution of steatosis in up to 95% of cases. Vertical sleeve gastrectomy (VSG) provided comparable hepatic benefits, significantly reducing liver fibrosis and steatosis in approximately 60% of patients. Adjustable gastric banding (AGB) demonstrated meaningful though comparatively modest hepatic improvements, with steatosis resolution in about 42% of patients. More aggressive procedures like biliopancreatic diversion with duodenal switch (BPD-DS) showed profound metabolic effects, though with increased nutritional risk. Endoscopic therapies, including intragastric balloon (IGB) and endoscopic sleeve gastroplasty (ESG), offered notable short- to medium-term hepatic improvements, significantly reducing steatosis and fibrosis markers. Newer therapies like duodenal mucosal resurfacing (DMR) and the duodenal-jejunal bypass liner showed promising preliminary results, warranting further investigation. Overall, surgical interventions remain superior for sustained liver health improvements, while endoscopic therapies present viable alternatives for patients requiring less invasive interventions.

Overview

CoChat Summary

TL;DR

This review synthesizes evidence on bariatric surgical and endoscopic interventions for MASLD/MASH, finding that surgery—especially RYGB—provides robust, durable hepatic improvements, while endoscopic therapies offer effective short-to-medium-term alternatives. RYGB achieved steatosis resolution in up to 95% of cases, VSG in about 60%, and AGB in about 42%, with endoscopic options reducing steatosis and fibrosis markers but requiring longer-term validation.

Key findings

  • RYGB showed steatosis remission in 89–95% of patients, MASH severity reduction of 75–88.9%, and full MASH remission in 38%; one-year NASH resolution without fibrosis progression occurred in 56% versus 16% with lifestyle modification alone (p < 0.0001). ALT fell by 28.5% at 6 months, 45% at 1 year, and 61.3% over 3 years.
  • VSG achieved NAFLD remission in 56% and steatosis remission in 56–68.4%; one cited study reported 100% MASH resolution. ALT decreased by 50% at 6 months (31.4 to 15.7 IU/L), and at 2 years VSG outperformed RYGB for ALT reduction (32.1% vs 15.4%).
  • AGB produced steatosis resolution in about 42% and modest NAS improvement (35.3%); in a paired-biopsy study, NASH criteria fell from 64% preoperatively to ~11% at follow-up, and significant fibrosis (stage ≥2) dropped from 18 to 3 patients (p < 0.001).
  • Endoscopic therapies showed short-to-medium-term benefits: IGB reduced NAS from 4 ± 2.25 to 2 ± 0.75 (p = 0.03) within 6 months and severe steatosis from 52% to 4% (p < 0.0001); ESG reduced NAFLD fibrosis score by 0.5 points, hepatic steatosis index by 4.85 points, and ALT by 6.32 U/L; DMR reduced ALT by 29.3% at 6 months; POSE 2.0 achieved complete steatosis resolution in 31.6% at 6 months and 52.6% at 12 months.

Methods

  • Systematic search of PubMed, MEDLINE, and Google Scholar using keywords including “MASLD,” “MASH,” “NAFLD,” “NASH,” “obesity,” “bariatric surgery,” “Roux-en-Y gastric bypass,” “sleeve gastrectomy,” “endoscopic sleeve gastroplasty,” and “intragastric balloon.”
  • Included randomized controlled trials, prospective and retrospective cohort studies, and meta-analyses examining liver histology, biochemical markers, liver enzymes, and non-invasive liver health assessments after intervention.
  • Data on clinical outcomes, safety profiles, and procedural effectiveness were extracted and synthesized thematically by procedure type, intervention outcomes, and time frame; quality was assessed with the Newcastle–Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for randomized controlled trials.

Limitations

  • Stated: evidence for endoscopic and emerging therapies remains limited, with calls for longer-term and larger-scale studies; MAS evidence is limited by small sample sizes and absence of control groups; DJBL effects on fibrosis remain inconclusive; POSE long-term efficacy needs confirmation; DMR’s long-term role requires further study.
  • Stated: BPD-DS carries risks of protein–calorie malnutrition, fat-soluble vitamin deficiencies, rare acute liver failure, and possible paradoxical fibrosis progression—one series found fibrosis worsened in 40% despite reduced steatosis.
  • Evident: this is a review without pooled meta-analysis, relying on heterogeneous observational studies, small trials, and variable endpoints; several included findings are drawn from single studies or incomplete follow-up.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jcm14124012

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

53 Valid · 4 Not valid · 134 Not checked · 51 Own results and interpretations

169 more claims · 36 with their cited sources checked

Create a free account to see all 242 claims and to verify the 11 references still open.

See all claims — free account
  • Probably not a substantial claim. 10
  • It may state two separate claims as one. 64

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 121 references

Cited by

See all 14

Metadata

Authors
Tasabehji, D., Saleh, S., & Mokadem, M.
Affiliations
University of Iowa (US)
Corresponding author
Mokadem, Mohamad
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2025-06-06
Volume
14
Issue
12
Pages
4012
ISSN
2077-0383 (ISSN-L)
OpenAlex
W4411101122
Cited by
14
References
121
Citations by year
2026: 11 · 2025: 3
FWCI
3.37
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • US Department of Veterans Affairs (I01 BX004774-05)
  • VA Merit Review Program (I01 BX004774-05)
  • Department Internal Medicine at University of Iowa Carver College of Medicine (I01 BX004774-05)
  • University of Iowa Fraternal Order of Eagles Diabetes Research Center (I01 BX004774-05)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Minimally Invasive Surgical Techniques
Keywords
non-alcoholic fatty liver disease, bariatric surgery, endoscopic treatment, Roux-en-Y gastric bypass, sleeve gastrectomy, gastric banding, biliopancreatic diversion with duodenal switch, intragastric balloon, endoscopic sleeve gastroplasty, duodenal mucosal resurfacing, duodenal-jejunal bypass liner, hepatic steatosis, liver fibrosis, liver inflammation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review. https://app.cochat.ai/papers/10.3390/jcm14124012
The paper
Tasabehji, D., Saleh, S., & Mokadem, M. (2025). Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review. Journal of Clinical Medicine. https://doi.org/10.3390/jcm14124012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.